bluebird bio Inc has hired apceth Biopharma GmbH to make its candidate ALD cell therapy Lenti-D and its thalassemia treatment LentiGlobin for the European market.
Acticor Biotech has made a deal with Merck KGaA’s CMO MilliporeSigma to use its Provantage End-to-End services to make its anti-thrombotic antibody fragment ACT-017 for stroke.
Sanofi has teamed with JHL Biotech to develop biosimilar products, including a version of Rituxan (rituximab), for the Chinese and international markets.
Synthetic biology firm Synpromics will use its PromPT promoter platform to increase stability and reduce the lead time for Sartorius Stedim Cellca’s CHO expression platform.
Valitacell has moved into the National Institute for Bioprocessing Research and Training (NIBRT) as it works to further develop its cell performance technologies.
A plan to attract advanced medicinal therapy manufacturing to the UK has emphasised the importance of the MHRA having a leading role in development of global regulatory standards.
Cel-Sci has responded to the partial clinical hold imposed on a Phase III trial of its candidate head and neck cancer cell therapy Multikine in September.
Selexis and Xencor have entered into a strategic agreement which strengthens an existing relationship for multi-specific antibody cell line development
The cell and gene therapy plant Lonza is building in Pearland, Texas will be bigger than originally planned to according to the city’s economic development corporation.
European stand-alone guidelines for the manufacture of Advanced Therapy Medicine Product (ATMP) could lead to disparities in GMP standards, says the Alliance for Regenerative Medicine.
Fixed-bed, high cell density bioreactors and a naturally occurring attenuated viral strain will be used by Batavia Biosciences in an attempt to produce an affordable rotavirus vaccine.
WuXi has responded to a global demand for perfusion technologies by opening a commercial scale manufacturing site in China with two 1,000L disposable bioreactors.
Horizon Discovery says flexibility and openness helped the UK’s Centre for Process Innovation (CPI) and Ireland’s NIBRT choose to provide its GS null CHO cell line to the biologics industry.
MilliporeSigma plans to use gene editing to help developers make cell lines resistant to viruses that cost manufacturers millions in contaminated products.
Mammalian cell line developer Selexis has signed a fourth licensing agreement in as many months and is planning a "major expansion" early next year ahead of anticipated demand.
Germany's Merck says gene editing can make CHO cells resistant to a tiny mouse virus that continues to be a problem for even animal component-free production processes.
The International Society for Cellular Therapy (ISCT) has called for a streamlined manufacturing regulatory pathway for cellular therapies to overcome the high upfront costs of manufacturing such products.
Asterias Biotherapeutics has selected Cognate BioServices for the process development and manufacture of its autologous dendritic cell vaccine candidate, AST-VAC1.
StemCells Inc has merged with Israeli medical devices firm Microbot Medical three months after terminating a Phase II trial of its HuCNS-SC human neural stem cells.
The US FDA has ordered Adaptimmune to halt a trial of its candidate liposarcoma therapy and asked for more information about how the treatment is made.
Epirus Biopharmaceuticals has filed for Chapter 7 bankruptcy protection, settled with licensee Livzon Mabpharm and handed its Remicade (infliximab) biosimilar to Reliance Life Sciences (RLS).
CAR-T therapy developer Kite Pharma has licensed rights to a culturing system that replicates conditions in the thymus from researchers at the University of California.
Axol Biosceince has teamed up with Metrion Biosciences to provide drug developers with a more accurate means of testing drugs' cardiac safety using stem cells.
Abzena will make Faron's drug candidate Clevegen - an antibody that neutralises a subset of immune cells linked to tumor proliferation - at a recently acquired single-use facility in California.
The US FDA’s decision to let Juno Therapeutics restart its JCAR015 trial is positive, but the CAR-T sector must learn from safety and efficacy findings says French biotech TxCell.
A human plasma protein could make producing pluripotent stem cells cheaper and faster according to academics in the UK and Sweden and partner GE Healthcare.
Anglo-American life science firm AMS Biotechnology has launched new cell lines to help companies researching the PD-1/PD-L1 pathway, one of the hottest areas of immuno-oncology research.
